News
Nature Biotechnology 25, 607 - 608 (2007)
Published online: 1 June 2007 | doi:10.1038/nbt0607-607
FDA likely to further restrict erythropoietin use for cancer patients
Jeffrey L. Fox1
- Washington
Abstract
FDA left no doubt after a May meeting that it plans to continue pressuring sponsors of erythropoiesis-stimulating agents for more definitive clinical data.
